tbuckley/cabot-search huggingface dataset:
Unreviewed Reports
Authors: D Ratliff, J Burns-
Journal: BMJ (1984)

Unreviewed ReportsAnaphylaxis to tetanus toxoid A healthy 76 year old woman attended the accident and emergency department with a splinter in her ring finger incurred while gardening and had it removed under ring anaesthesia with 4 ml 2% lignocaine.She was given 0-5 ml adsorbed tetanus toxoid; within one hour she became acutely dypsnoeic and was readmitted as a cardiac emergency with bronchospasm.She was resuscitated from respiratory arrest, asystole, and two grand mal convulsions, with adrenaline, hydrocortisone, phenytoin, and chlorpheniramine.She was artificially ventilated overnight and was discharged three days later.Our patient experienced anaphylaxis to tetanus toxoid, which is the first described case in the United Kingdom.We believe all patients receiving this treatment should be close to medical help for one hour after administration.-
Military medicine tries 'home front' approaches
Authors: P. Gunby
Journal: JAMA (1997)

TODAY'S peace enforcement effort in the former Yugoslavia is the 50th military operation involving US troops since the 1989 Just Cause move into Panama. Military medicine has supported all of them, in the field and at home. The home base effort has become more important than ever as the dwindling number of US troops are deployed increasingly often and for longer periods, leaving spouses and children behind. To take care of these beneficiaries awaiting the return of their family member in uniform, US military medical personnel—whose numbers also have decreased with the downsizing of the armed services—are exploring a number of approaches. At Landstuhl (Germany) Regional Medical Center, for example, "Army" has been dropped from this major referral (for 250 000 beneficiaries throughout Europe) facility's title because US Air Force physicians and other medical personnel have joined their US Army counterparts there. In Würzburg, Germany, Ronald R. Blanck, DO, visiting
Abstract P396: Thirty Years of Cardiovascular Mortality in Quebec, is the Decline Slowing in the Younger Population?
Authors: Claudia Blais, Denis Hamel
Journal: Circulation (2012)

Background: It has been demonstrated in many countries that cardiovascular mortality has decreased over recent decades and the decline was accelerating for people aged 35 years and older and slowing in the younger population. Coronary heart disease (CHD) and stroke were the major causes responsible of this decline. We hypothesized that this fall and deceleration of the decline has occurred also in Quebec, Canada and looked if other diseases, such as heart failure (HF) and high blood pressure (HBP) presented a similar decline. Methods: Age-adjusted and specific mortality rates were obtained with the Quebec registry of death for each year of 1978–2007 period for all cardiovascular diseases and divided into CHD, stroke, HF and HBP for people aged ≥35 years and for each 10 year-age groups respectively. Joinpoint regressions on these mortality rates were used to estimate the annual percentage change (APC) and to detect points in time at which significant changes in the trends occurred. Several methods of forecasting were compared to predict age-adjusted mortality rates for the next decade (2008–2017). Results: There were 542,712 cardiovascular deaths. All CHD age-adjusted mortality rates for both sexes combined declined with a marked acceleration in 1997 (APC 1978–1997 and 1997–2007 of −3.05 and −5.99 respectively) while stroke presented with a lower decline between years 1988 and 1997 and reaccelerated thereafter (APC 1978–1988: −4.72, 1988–1997: −2.22 and 1997–2007: −5.39). HF presented an increase between years 1978 and 1981 (APC: 6.28) followed by a decline (APC 1981–2007: −3.58). Death due to HBP in the same group showed a deceleration of the decline in 1992 (APC 1978–1992: −7.46 and APC 1992–2007: −1.97). In the group aged 35–44 years, when both sexes were combined, only HF presented an increase in the mortality rate (APC 1978–1992: −7.76 and 1992–2007: 4.97). CHD and stroke presented constant declines for this age group (APC 1978-2007: −5.17 and −4.73, respectively) while HBP had no mortality at all. CHD mortality for all ages is projected to decrease to an adjusted rate of 100 per 100,000 person-year in 2017 (−38% from 2007). Conclusions: Death due to HBP was the only cause responsible of a slowing of the decline in people aged 35 years and older. However, when looking at the younger population, HF is presenting not only a slowing of the decline but, more importantly, an increase in the mortality rate. The forecasting of cardiovascular deaths seems to get a constant decline for the principal cause, CHD.
Oxaliplatin plus continuous infusion topotecan: An ongoing phase II study for recurrent ovarian cancer—A New York Cancer Consortium study (#N01-CM62204).
Authors: S. Stein, H. S. Hochster, F. Muggia, S. V. Blank, J. P. Curtin, I. Shapira, G. L. Goldberg, A. Tiersten
Journal: Journal of Clinical Oncology (2010)

5092 Background: Topoisomerase-1 inhibitors and platinums are active in ovarian cancer. Our prior series described infusional topotecan as less myelosuppressive than bolus and more easily combined with oxaliplatin than cisplatin. An NYU phase I study of the combination in previously treated ovarian cancer patients (pts) showed promising activity and good tolerability (Hochster, H, Gynecol Oncol 2008). Methods: Ovarian cancer pts treated with 1-2 prior regimens (1 platinum/taxane regimen, no topotecan) were treated with oxaliplatin 85 mg/m2 day 1, 15 and topotecan (0.4 mg/m2/day) continuous infusion × 14 days every 4 weeks (wks). Platinum resistant (stratum I = 18) and sensitive (stratum II = 19) pts are included in this trial to evaluate overall response rate (ORR) and toxicities. Results: From 1/06-12/09, 37 pts entered. Median age was 60 (38-80). 19 pts had 1 prior regimen and 18 pts had 2. Nine pts discontinued before completing 2 cycles (4 for predefined toxicity, 3 by pt/physician choice, and 2 for progression of disease). 141 cycles of chemotherapy were given (median 4, [1-6]). Grade 3/4 toxicities included thrombocytopenia (27% grade 3, 16% grade 4), neutropenia (22% grade 3, 8% grade 4), anemia (14% grade 3). 27 pts had day 15 oxaliplatin held, 14 pts required dose reductions, and 28 pts had treatment delays mainly from thrombocytopenia. No pts had neutropenic fever. Stratum I had 3 complete and 2 partial responses, 5 pts with stable disease and 4 with progressive disease (4 pts were not assessable). Stratum II had 3 complete and 5 partial responses, 5 pts with stable disease and 1 pt with progression (5 pts were not assessable). Conclusions: An ORR of 36% in platinum resistant patients and 57% in platinum sensitive patients is highly encouraging. Excluding thrombocytopenia, tolerance to this regimen confirms phase I results. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration sanofi-aventis
Aesculapius
Authors: SAUL B. GILSON
Journal: Annals of Internal Medicine (1980)

Ad Libitum1 April 1980AesculapiusSAUL B. GILSON, M.D.SAUL B. GILSON, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-92-4-566_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptA kindly lieHelps an old man die.A harsher truthIn another placeScrews a silent screamTo an old wife's face.Lies cramp the throatAnd sand the eye.Truth grows a cancer in the sideAnd the old man soon will die.Love for all,Love for a feeUnprized if freeThey buy of my finite flesh.I serve with my fleshThe sick who refreshAt the sources of my desire.... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: SAUL B. GILSON, M.D. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1980Volume 92, Issue 4 Page: 566-566 Keywords Pharynx ePublished: 1 December 2008 Issue Published: 1 April 1980 PDF downloadLoading ...
AIDS Doctor
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The United States Needs a Health System Like Other Countries
Authors: Roger A. Forsyth
Journal: JAMA (1994)

<h3>To the Editor.</h3> —The article by Dr Glaser,<sup>1</sup>which recommends a "genuine national health insurance system," dismisses criticisms that such a system leads to "backward technologies, waiting lists, [and] underpaid... physicians," but does not provide any justification for that dismissal. On the other hand, one can readily justify the criticisms. For example, a recent article<sup>2</sup>stated that France provides dialysis to 88% fewer of its citizens than does the United States, and physician income is only 30% of the US level. Short visits and long waiting lists are a feature of every national health insurance system. These facts should make one pause before recommending a change. What is the virtue of correcting the United States' sin of high expenditures by substituting the sin of inadequate expenditures under a government-mandated global budget? Similarly, the article summarily dismisses the proposed middle ground of managed competition. The author states that hospital
Second Moment Method for Evaluating Human Health Risks from Groundwater Contaminated by Trichloroethylene
Authors: Timothy L. Jacobs, John M. Warmerdam, Miguel A. Medina, Warren T. Piver
Journal: Environmental Health Perspectives (1996)

Pollutants in groundwater aquifers may constitute a significant human health risk. A large variation in response may result among human populations experiencing the same level and duration of exposure to pollutants. Variability in response, as a result of exposure to a carcinogenic contaminant such as trichloroethylene (TCE), can be represented by a distribution function of safe doses. Spatial variability in aquifer characteristics and contaminant transport parameters requires the use of stochastic transport models to quantify variability in exposure concentrations. A second moment method is used to evaluate the probability of exceeding safe dose levels for a contaminated aquifer. The name of this method stems from the fact that the formulation is based on the first and second moments of the random variables. With this method, the probability is a function of the variability of contaminant concentration (which incorporates variability in hydrogeologic parameters such as hydraulic conductivity) and the variability in response in the human population. In this manner, the severity of the health risk posed by a contaminated aquifer and the evaluation of appropriate strategies and technologies for aquifer remediation are a function of contaminant concentrations and human health risks. The applicability and limitations of this method are demonstrated with data on groundwater contaminated by TCE at Hill Air Force Base, Utah.
Masthead: (Adv. Healthcare Mater. 3/2019)
Journal: Advanced Healthcare Materials (2019)

Citizenship: Wiley's Corporate Citizenship initiative seeks to address the environmental, social, economic, and ethical challenges faced in our business and which are important to our diverse stakeholder groups.Since launching the initiative, we have focused on sharing our content with those in need, enhancing community philanthropy, reducing our carbon impact, creating global guidelines and best practices for paper use, establishing a vendor code of ethics, and engaging our colleagues and other stakeholders in our efforts.
The Health of the City.
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Social Scene
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Method Development and Subsequent Survey Analysis of Biological Tissues for Platinum, Lead, and Manganese Content
Authors: Anna M. Yoakum, Peggy L. Stewart, Janice E. Sterrett
Journal: Environmental Health Perspectives (1975)

An emission spectrochemical method is described for the determination of trace quantities of platinum, lead, and manganese in biological tissues. Total energy burns in an argon-oxygen atmosphere are employed. Sample preparation, conditions of analysis, and preparation of standards are discussed. The precision of the method is consistently better than +/- 15%, and comparative analyses indicate comparable accuracies. Data obtained for experimental rat tissues and for selected autopsy tissues are presented.
Overview of a workshop on quantitative models for developmental toxicity risk assessment
Authors: Carole A. Kimmel, Dorothy G. Wellington, William Farland, Philip Ross, Jeanne M. Manson, Neil Chernoff, John F. Young, Sherry G. Selevan, Norman Kaplan, Chao Chen, Laurence D. Chitlik, Cheryl L. Siegel-Scott, Georgia Valaoras, Suzanne Wells
Journal: Environmental Health Perspectives (1989)

A workshop was held to discuss potential advancements to improve the precision of risk estimates for developmental toxicity. This paper presents an overview of the discussions at the workshop, focusing on the risk assessment process and science policy considerations important in the use of quantitative models. Some of the pertient biological considerations are reviewed, particularly those related to the repair capacity of the developing organism and how this affects the concept of a threshold for developmental toxicity effects, as well as the maternal and litter influences on developmental toxicity outcomes. Finally, the current status of use of quantitative approaches is described, possible short-term approaches are discussed, and future research needs in this area are outlined.
Manpower.
Authors: S Brearley
Journal: BMJ (1992)

Manpower is accorded just two thirds of a page in Leading for Health: a BMA Agenda for Health,' yet its importance in the overall strategy of health care provision cannot be overemphasised.Many of the other issues discussed in the document have manpower consequences, not only for doctors but also for nurses, other professional groups, and ancillary staff.The NHS is the largest employer in Europe and some 70% of its budget is spent on salaries and wages.For these reasons alone manpower demands serious consideration by anyone intent on drawing up a blueprint for a health service in the year 2000.
PWE-077 Residual Intestinal Metaplasia after Successful Endoscopic Therapy for Barrett’s Related Neoplasia Confers Higher Long Term Risk for Disease Recurrence, on Behalf of The UK RFA Registry
Authors: G Lipman, A Gupta, JM Dunn, D Morris, H Smart, P Bhandari, RP Willert, G Fullarton, AJ Morris, M Di Pietro, C Gordon, I Penman, H Barr, P Patel, P Boger, N Kapoor, BS Mahon, J Hoare, R Narayanasamy, D O’Toole, Y Ang, A Veitch, D Nylander, A Dhar, K Ragunath, A Leahy, M Fullard, R Haidry, LB Lovat
Journal: Gut (2016)

<h3>Introduction</h3> Endoscopic resection (ER) followed by Radiofrequency ablation (RFA) is the first line treatment for neoplastic Barrett’s oesophagus (BE). Metachronous neoplasia after focal eradication of disease is ~20%. We examine data from the UK registry of 28 centres to establish if residual metaplastic BE carries a risk of disease recurrence. <h3>Methods</h3> Visible lesions were removed by EMR. Patients then underwent RFA 3 monthly. Biopsies were taken at 12 months to assess treatment success with repeat biopsies every 6–12 months thereafter. Dysplasia recurrence was compared in patients who had complete reversal of BE and neoplasia (CR-IM) to those in whom dysplasia alone was eradicated (CR-D only). Residual BE was confirmed with visible columnar epithelium proximal to the OGJ with biopsies showing IM. <h3>Results</h3> 517 patients achieved CR-IM &amp; 96 patients achieved CR-D only after 12 months treatment . Sex &amp; ER rates were not significantly different between groups. The CR-D only group were older (mean age 70 vs 67, p &lt; 0.01) and had longer initial BE (mean length 6.2 cm vs 4.7 cm, p &lt; 0.0001). Mean residual BE length was 1.4 cm. At median follow up 32 months, more patients were disease free in the CR-IM group (96% vs 89%) and Kaplan Meier statistics demonstrated an improved predicted 6 year neoplasia free survival in the CR-IM group (90% vs 84% log rank p 0.0015). Most recurrences occurred within 3 years of follow up. <h3>Conclusion</h3> Endotherapy should aim to clear neoplasia and underlying metaplastic BE to improve long term outcome. Patients with CR-D but not CR-IM at the end of treatment have an increased risk of neoplasia recurrence. This may have implications for post treatment surveillance intervals. <h3>Disclosure of Interest</h3> None Declared
Nitroprusside
Authors: JAY N. COHN
Journal: Annals of Internal Medicine (1979)

Sodium nitroprusside has proved to be the most effective and best-tolerated vasodilator drug available for the management of acute hypertension, heart failure, and other vasoconstricted states as well as for the induction of controlled hypotension during surgery. It dilates both arteries and veins, has a rapid onset and offset of action, and is almost uniformly effective in achieving the desired degree of dilation by careful dosage titration. The need for close monitoring of its intravenous administration and the potential toxicity of prolonged infusions limit its general use from periods of hours to a few days, but its unique and usually well-maintained vascular actions make it an ideal agent for short-term therapy and a potentially useful model for development of new, orally effective vasodilator drugs.
Problems in Evaluating Radiation Dose via Terrestrial and Aquatic Pathways
Authors: Burton E. Vaughan, Joseph K. Soldat, R. Gene Schreckhise, Edwin C. Watson, Daniel H. McKenzie
Journal: Environmental Health Perspectives (1981)

This review is concerned with exposure risk and the environmental pathways models used for predictive assessment of radiation dose. Exposure factors, the adequacy of available data, and the model subcomponents are critically reviewed from the standpoint of absolute error propagation. Although the models are inherently capable of better absolute accuracy, a calculated dose is usually overestimated by from two to six orders of magnitude, in practice. The principal reason for so large an error lies in using "generic" concentration ratios in situations where site specific data are needed. Major opinion of the model makers suggests a number midway between these extremes, with only a small likelihood of ever underestimating the radiation dose. Detailed evaluations are made of source considerations influencing dose (i.e., physical and chemical status of released material); dispersal mechanisms (atmospheric, hydrologic and biotic vector transport); mobilization and uptake mechanisms (i.e., chemical and other factors affecting the biological availability of radioelements); and critical pathways. Examples are shown of confounding in food-chain pathways, due to uncritical application of concentration ratios. Current thoughts of replacing the critical pathways approach to calculating dose with comprehensive model calculations are also shown to be ill-advised, given present limitations in the comprehensive data base. The pathways models may also require improved parametrization, as they are not at present structured adequately to lend themselves to validation. The extremely wide errors associated with predicting exposure stand in striking contrast to the error range associated with the extrapolation of animal effects data to the human being.